Skip to content
StockMarketAgent
Direct answer
Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion. Fair value range: low $55.9, high $85.0, with mid-point at $70.4.
Stock analysis

BSX BSX fair value $56–$85

BSX
By StockMarketAgent.AI team· supervised by
Analyzed: 2026-05-12Next update: 2026-08-12Methodology v2.4Review: automatedArchetype: Mature compounder
View archive
Last price
$54.10
▲ +16.29 (+30.11%)
Fair value
$70
$56–$85
Rating
Strong Buy
confidence 88/100
Upside
+30.1%
upside to fair value
Margin of Safety
$59.83
MoS level · 15%
Market Cap
$80.4B
P/E fwd 14.4

§1 Executive summary

  • Strong Buy rating driven by 30% upside to $70.39 composite fair value midpoint.
  • Mature compounder profile translates high ROE into durable EPS growth with fading downside risk.
  • Q1 revenue growth of 11.6% outpaces major cardiovascular and MedSurg peers.
  • Valuation explicitly bridges benchmark optimism with structural terminal constraints via a moat-fade framework.
Fair value
$70
Margin of safety
+23.1%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$54.10Price
Low $55.91
Mid $70.39
High $85.05

Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion.

  • High switching costs in implantable
    High switching costs in implantable MedSurg devices.
  • Intangible assets via robust IP
    Intangible assets via robust IP in structural heart (WATCHMAN).
  • Cycle upside
    Demographic tailwinds and deferred elective procedure catch-up drive sustained, above-trend cardiovascular demand.

§2 Bear case

A severe macro shock testing hospital capital budgets exposes operating leverageLeverageThe proportion of debt in the company's capital structure. Commonly measured as Debt/EBITDA, Debt/Equity, or Net Debt/EBITDA. risks. With high fixed costs and a reinvestment rate of 82.6%, a top-line deceleration below 6% rapidly compresses the 20% operating marginOperating marginOperating income (EBIT) divided by revenue. Captures profitability after both direct costs and operating expenses but before interest, tax, and non-operating items., forcing fair valueFair valueOur composite estimate of intrinsic per-share value, blended across DCF, exit-multiple, and reverse-DCF methods. Reported as a low/mid/high range to capture model uncertainty. down toward the $55.91 bear floor.

Ways this thesis can break

Multiple Compression to Peer Median

· Medium

Premium valuation collapses as the market forces reversion to peer median PEG ratios.

FV impact
Valuation plunges to $40.05 peg_adjusted_peer level.
Trigger
12-24 months

Reimbursement Rate Cuts

· Low

Medicare reimbursement cuts and hospital consolidation severely erode structural pricing power.

FV impact
Midpoint fair value drops to the $55.91 bear boundary.
Trigger
12-36 months

WATCHMAN Normalization Stall

· Medium

Accelerated market share gains in the structural heart segment fail, normalizing revenue growth abruptly.

FV impact
Pulls valuation below the $61.91 FCFF DCF baseline.
Trigger
6-18 months
Early-warning signals to monitor
MetricCurrentTrigger threshold
Revenue growth decelerates below 6% falsification trigger.MonitorDeterioration versus the report thesis
Operating margins fail to sustain the 20.0% normalized assumption.MonitorDeterioration versus the report thesis
Peer forward P/E multiples compress, dragging the premium valuation.MonitorDeterioration versus the report thesis
Regulatory setbacks in the cardiac rhythm management pipeline.MonitorDeterioration versus the report thesis
Free cash flow conversion drops below 1.0x net income.MonitorDeterioration versus the report thesis

§3 Financial history

Income statement — last six periods
Line itemT−0T−1T−2T−3T−4CAGR
Period2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
Revenue$11.89B$12.68B$14.24B$16.75B$20.07B+14.0%
Gross profit$8.18B$8.73B$9.90B$11.49B$13.85B+14.1%
Operating income$1.82B$2.03B$2.42B$3.00B$3.97B+21.5%
Net income$1.04B$698.0M$1.59B$1.85B$2.90B+29.2%
EPS (diluted)$0.69$0.45$1.07$1.25$1.94+29.5%
EBITDA$2.51B$2.75B$3.45B$3.86B$5.10B+19.4%
R&D$1.20B$1.32B$1.41B$1.62B$2.05B+14.3%
SG&A$4.36B$4.52B$5.19B$5.98B$6.89B+12.1%

Quality scores

OCF / Net income
1.57×
>1 indicates high earnings quality
Accounting quality gate
Fail
Sector-adjusted gate
ROIC
8.3%
Return on invested capital
§3

Numbers analysis

Individual subscribers — §4 onwards11 more sections

Read the full analysis — 11 more sections.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Full report for every covered ticker
24 months of rating archive
Watchlist briefings + rating-change alerts
PDF + DOCX export in any language
Start free trial
Cancel anytime.
FAQ

BSX — frequently asked questions

  1. Based on our latest analysis, BSX looks meaningfully undervalued. The current price is $54.1 versus a composite fair-value midpoint of $70.4 (range $55.9–$85.0), which implies roughly 30.1% upside to the midpoint.

Related coverage

Names readers of BSX also follow

Same archetype: mature-compounder